This week, in our final podcast of 2022, now we have two friends. We’ve conversations with Talat Imran, CEO of Rani Therapeutics; and Stef van Grieken, CEO and co-founder of Cradle.

Rani Therapeutics – aiming to take away the ache of needles

Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics firm targeted on the oral supply of biologics and medicines, has introduced topline outcomes from half 2 (the repeat-dose portion) of the section 1 examine of RT-102, the RaniPill GO capsule containing a proprietary formulation of human parathyroid hormone (1-34) analog (PTH) being developed for the remedy of osteoporosis. 

The examine achieved all of its endpoints, with repeat doses of RT-102 being typically nicely tolerated and delivering the drug with excessive reliability to members by way of the RaniPill GO.

With these knowledge, in complete, 185 RaniPill GO capsules have now been administered to greater than 90 members in medical research, along with over 1,700 RaniPill capsules administered to animals in preclinical research. Within the medical research, the RaniPill capsule has been nicely tolerated and delivered its drug payload with excessive reliability and with bioavailability similar to or higher than subcutaneous injection.

“The repeat-dose knowledge contribute to our rising physique of preclinical and medical knowledge that we consider assist the viability of the RaniPill platform to orally ship biologics and medicines to deal with continual ailments,” stated Talat Imran, CEO of Rani. 

“These knowledge give us confidence to maneuver ahead with a number of applications in parallel, together with our ustekinumab biosimilar and adalimumab biosimilar applications, and to develop manufacturing scale-up. We are able to see a future the place tens of millions of sufferers now not carry the burden of normal injections.”

Startup Cradle raises $5.4M to design protein machines and cell factories with AI

Cradle, a Dutch biotech startup, has acquired €5.5 million ($5.4 million) in seed funding to additional assist scientists design and program proteins to supply all kinds of on a regular basis merchandise together with milk and meat.

Cradle makes use of artificial biology, adapting the genes of microorganisms resembling micro organism and fungi, to create ‘cell factories’ that use programmable proteins to make quite a few merchandise with out farming animals, to plastics created with out petrochemicals, supplies for clothes or digital elements, and even customized medicines.

Source link